newsfilter
← Latest News
PR Newswire·

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

SARASOTA, Fla., March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment